AZ Biopharm

Executive Summary

AZ Biopharm GmbH is an independent, FDA-inspected, GLP/GMP/GCP-certified contract research organization (CRO) headquartered in Berlin, Germany. Founded in 2018, the company offers a comprehensive suite of analytical services including pharmaceutical analytics, bioanalytics, nitrosamine and cannabis testing, method development, and stability testing. Serving as a single-source supplier for quality control and bioanalytical support, AZ Biopharm supports both preclinical and clinical studies. Its certifications and independent status position it as a reliable partner for pharmaceutical and biotech companies seeking high-quality analytical services. As a private, pre-clinical stage CRO, AZ Biopharm operates in a competitive market but differentiates itself through its broad service portfolio and regulatory compliance. The company is well-positioned to benefit from increasing outsourcing trends in drug development, particularly in specialized areas like nitrosamine testing and cannabis analytics. Growth is expected to be driven by expanding client relationships, service diversification, and potential entry into new geographic markets. While the company does not have publicly disclosed financials nor major near-term clinical catalysts, its steady service business model provides a stable revenue base and opportunities for moderate growth.

Upcoming Catalysts (preview)

• Q3 2026New GLP/GMP certification renewal or FDA re-inspection outcome85% success
• Q4 2026Major multi-year contract with a top-20 pharmaceutical company30% success
• Q2 2026Launch of expanded cannabis testing service line60% success